Evaluation of the Abbott ARCHITECT Chagas prototype assay.

Gerald Praast1, Jörg Herzogenrath, Stephanie Bernhardt

  • 1Abbott GmbH & Co. KG, Wiesbaden-Delkenheim, Germany. gerald.praast@abbott.com

Summary

New serologic tests improve Chagas disease diagnosis. The Abbott ARCHITECT Chagas assay shows superior sensitivity and specificity compared to existing enzyme-linked immunosorbent assays (ELISAs), offering reliable Trypanosoma cruzi infection detection.

Related Concept Videos